Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 1;29(1):38-41.
doi: 10.1097/PRA.0000000000000690.

Comparative Pharmacology of the 3 Marketed Dual Orexin Antagonists-Daridorexant, Lemborexant, and Suvorexant-Part 2. Principal Drug Metabolizing Enzyme, Drug-Drug Interactions, and Effects of Liver and Renal Impairment on Metabolism

Sheldon H Preskorn  1
Affiliations

Comparative Pharmacology of the 3 Marketed Dual Orexin Antagonists-Daridorexant, Lemborexant, and Suvorexant-Part 2. Principal Drug Metabolizing Enzyme, Drug-Drug Interactions, and Effects of Liver and Renal Impairment on Metabolism

Sheldon H Preskorn. J Psychiatr Pract. .

Abstract

This column is the second in a 2-part series presenting the comparative pharmacology of the 3 Food and Drug Administration-approved dual orexin receptor antagonists, daridorexant, lemborexant, and suvorexant. Both of the columns in this series emphasize the pharmacokinetics of these drugs as they are relevant to their use as sleep medications. Although other classes of sleep medications are not discussed, the same pharmacokinetic principles also apply to them in terms of endeavoring to match the pharmacokinetics of an agent to the individual's usual sleep cycle. This second column in the series focuses on the metabolism of each of the 3 drugs by the cytochrome P450 enzyme CYP3A, guidance for using these agents in combination with drugs that are CYP3A inhibitors or inducers, and how to adjust dosing in patients with comorbid conditions such as hepatic or renal impairment.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. BELSOMRA® (Suvorexant) Prescribing Information. Rahway, NJ: Merck Sharp & Dohme; May 2022. Accessed September 24, 2022. https://www.merck.com/product/usa/pi_circulars/b/belsomra/belsomra_pi.pdf
    1. DAYVIGO (Lemborexant) Prescribing Information. Nutley, NJ: Eisai. March 2022. Accessed September 24, 2022. https://www.dayvigohcp.com/-/media/Files/DAYVIGOHCP/PDF/prescribing-info...
    1. QUVIVIQ (Daridorexant) Prescribing Information. Radnor, PA: Idorsia Pharmaeuticals US. April 2022. Accessed September 24, 2022. https://www.idorsia.us/documents/us/label/Quviviq_PI.pdf
    1. Preskorn SH. Comparative pharmacology of the 3 marketed dual orexin antagonists-daridorexant, lemborexant, and suvorexant: part 1: pharmacokinetic profiles. J Psychiatr Pract. 2022;28:478–480.
    1. Preskorn SH. Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: an update (part I). J Psychiatr Pract. 2003;9:150–158.

LinkOut - more resources